Lilly completes acquisition of Dermira
INDIANAPOLIS — Eli Lilly and Co. announced the successful completion of its acquisition of Dermira. The acquisition expands Lilly’s immunology pipeline with the addition of lebrikizumab, a novel, investigational, monoclonal antibody designed to bind IL-13 with high affinity that is being evaluated in a Phase 3 clinical development program for the treatment of moderate-to-severe atopic
